专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008008374A2 CCR2 INHIBITORS AND METHODS OF USE THEREOF 审中-公开
标题翻译： CCR2抑制剂及其使用方法
公开(公告)号：WO2008008374A2
公开(公告)日：2008-01-17
申请号：PCT/US2007/015785
申请日：2007-07-10
申请人： CHEMOCENTRYX, INC. , BASAK, Arindrajit , JIN, Jeff , MOORE, Jimmie , PENNELL, Andrew, M., K. , PUNNA, Sreenivas , UNGASHE, Solomon , WEI, Zheng
发明人： BASAK, Arindrajit , JIN, Jeff , MOORE, Jimmie , PENNELL, Andrew, M., K. , PUNNA, Sreenivas , UNGASHE, Solomon , WEI, Zheng
CPC分类号： A61K31/44 , A61K31/47 , A61K31/5375 , C07C311/21 , C07D207/16 , C07D213/42 , C07D213/50 , C07D231/12 , C07D263/32 , C07D295/108 , C07D295/192
摘要： Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists, and as controls in assays for the identification of CCR9 antagonists.
摘要翻译：提供了作为CCR2或CCR9受体的有效拮抗剂的化合物。动物试验表明，这些化合物可用于治疗炎症，CCR2和CCR9的标志性疾病。化合物通常是芳基磺酰胺衍生物，并且可用于药物组合物，用于治疗CCR2介导的疾病的方法，CCR9介导的疾病，作为用于鉴定CCR2拮抗剂的测定中的对照，以及用于鉴定CCR9的测定中的对照拮抗剂。

2. 发明申请

WO2008008431A2 HETEROARYL SULFONAMIDES AND CCR2/CCR9 审中-公开
标题翻译： HETEROARYL SULFONAMIDES和CCR2 / CCR9
公开(公告)号：WO2008008431A2
公开(公告)日：2008-01-17
申请号：PCT/US2007/015893
申请日：2007-07-12
申请人： CHEMOCENTRYX, INC. , DAIRAGHI, Daniel , CHARVAT, Trevor, T. , MOORE, Jimmie , HANSEN, Derek , CHEN, Wei , JIN, Jeff , KRASINSKI, Antoni , BASAK, Arindrajit , WEI, Zheng , WANG, Qiang , UNGASHE, Solomon , WRIGHT, John, J. , PUNNA, Sreenivas , PENNELL, Andrew, M.k. , ZENG, Yibin
发明人： DAIRAGHI, Daniel , CHARVAT, Trevor, T. , MOORE, Jimmie , HANSEN, Derek , CHEN, Wei , JIN, Jeff , KRASINSKI, Antoni , BASAK, Arindrajit , WEI, Zheng , WANG, Qiang , UNGASHE, Solomon , WRIGHT, John, J. , PUNNA, Sreenivas , PENNELL, Andrew, M.k. , ZENG, Yibin
CPC分类号： A61K31/444 , A61K31/437 , A61K31/4439 , A61K45/06 , C07C311/21 , C07D213/75 , C07D241/22 , C07D401/06 , C07D401/10 , C07D407/04 , C07D409/12 , C07D413/06 , C07D417/12 , C07D471/04 , C07D498/04
摘要： Compounds are provided that act as potent antagonists of the CC R2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CC R2 antagonists.
摘要翻译：提供了作为CCR2受体的有效拮抗剂的化合物。动物实验表明，这些化合物可用于治疗炎症，CCR2的标志性疾病。化合物通常为芳基磺酰胺衍生物，并且可用于药物组合物，用于治疗CCR2介导的疾病的方法，以及用于鉴定CCR2拮抗剂的测定中的对照。

3. 发明申请

WO2008008375A2 TRIAZOLYL PYRIDYL BENZENESULFONAMIDES 审中-公开
标题翻译：三唑基吡啶二苯并呋喃
公开(公告)号：WO2008008375A2
公开(公告)日：2008-01-17
申请号：PCT/US2007/015786
申请日：2007-07-10
申请人： CHEMOCENTRYX, INC. , CHARVAT, Trevor, T. , HU, Cheng , JIN, Jeff , LI, Yandong , MELIKIAN, Anita , PENNELL, Andrew, M.K. , PUNNA, Sreenivas , UNGASHE, Solomon , ZENG, Yibin
发明人： CHARVAT, Trevor, T. , HU, Cheng , JIN, Jeff , LI, Yandong , MELIKIAN, Anita , PENNELL, Andrew, M.K. , PUNNA, Sreenivas , UNGASHE, Solomon , ZENG, Yibin
IPC分类号： C07D401/04 , C07D401/14 , A61K31/4439 , A61P9/10
CPC分类号： C07D401/14
摘要： Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.
摘要翻译：提供了作为CCR2或CCR9受体的有效拮抗剂的化合物。动物试验表明，这些化合物可用于治疗炎症，CCR2和CCR9的标志性疾病。化合物通常为芳基磺酰胺衍生物，并且可用于药物组合物，用于治疗CCR2介导的疾病，CCR9介导的疾病的方法，作为用于鉴定CCR2拮抗剂的测定中的对照和用于鉴定CCR9拮抗剂的测定中的对照。

4. 发明申请

WO2008010934A2 TRIAZOLYL PHENYL BENZENESULFONAMIDES 审中-公开
标题翻译：三唑基苯并噻二唑
公开(公告)号：WO2008010934A2
公开(公告)日：2008-01-24
申请号：PCT/US2007/015808
申请日：2007-07-10
申请人： CHEMOCENTRYX, INC. , CHARVAT, Trevor, T. , HU, Cheng , MELIKIAN, Anita , NOVACK, Aaron , PENNELL, Andrew, M.K. , SULLIVAN, Edward, J. , TAN, Xuefei , THOMAS, William, D. , UNGASHE, Solomon , ZENG, Yibin , PUNNA, Sreenivas
发明人： CHARVAT, Trevor, T. , HU, Cheng , MELIKIAN, Anita , NOVACK, Aaron , PENNELL, Andrew, M.K. , SULLIVAN, Edward, J. , TAN, Xuefei , THOMAS, William, D. , UNGASHE, Solomon , ZENG, Yibin , PUNNA, Sreenivas
CPC分类号： C07D401/04 , C07D249/08 , C07D403/04 , C07D405/04 , C07D405/12 , C07D413/04
摘要： Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.
摘要翻译：提供了作为CCR2或CCR9受体的有效拮抗剂的化合物。动物实验表明，这些化合物可用于治疗炎症，CCR2和CCR9的标志性疾病。化合物通常为芳基磺酰胺衍生物，并且可用于药物组合物，用于治疗CCR2介导的疾病，CCR9介导的疾病的方法，作为用于鉴定CCR2拮抗剂的测定中的对照和用于鉴定CCR9拮抗剂的测定中的对照。

5. 发明申请

WO2011035332A1 PYRROLIDINONE CARBOXAMIDE DERIVATIVES AS CHEMERIN-R ( CHEMR23 ) MODULATORS 审中-公开
标题翻译：作为CHEMERIN-R（CHEMR23）调节剂的吡咯烷酮羧酰胺衍生物
公开(公告)号：WO2011035332A1
公开(公告)日：2011-03-24
申请号：PCT/US2010/049718
申请日：2010-09-21
申请人： CHEMOCENTRYX, INC. , CHARVAT, Trevor T. , CHU, Hiufung , KRASINSKI, Antoni , LANGE, Christopher W. , LELETI, Manmohan Reddy , POWERS, Jay P. , PUNNA, Sreenivas , SULLIVAN, Timothy J. , UNGASHE, Solomon
发明人： CHARVAT, Trevor T. , CHU, Hiufung , KRASINSKI, Antoni , LANGE, Christopher W. , LELETI, Manmohan Reddy , POWERS, Jay P. , PUNNA, Sreenivas , SULLIVAN, Timothy J. , UNGASHE, Solomon
IPC分类号： C07D209/46 , C07D209/52 , C07D401/06 , C07D403/06 , C07D405/04 , C07D493/04 , C07D207/416 , A61K31/4025 , A61P29/00
CPC分类号： C07D207/277 , C07D207/416 , C07D209/46 , C07D209/52 , C07D401/04 , C07D401/06 , C07D403/06 , C07D405/04 , C07D413/06 , C07D491/048 , C07D491/052 , C07D493/04
摘要： Pyrrolidinone carboxamide compounds of formula (I) are provided that are useful for inhibiting the binding of ligands to the ChemR23 receptor.
摘要翻译：提供式（I）的吡咯烷酮羧酰胺化合物，其可用于抑制配体与ChemR23受体的结合。

6. 发明申请

WO2009038847A1 N-(2-(HETARYL)ARYL)ARYLSULFONAMIDES AND N-(2-(HETARYL)HETARYL)ARYLSULFONAMIDES 审中-公开
标题翻译： N-（2-（HETARYL）ARYL）ARYLSULFONAMIDES和N-（2-（HETARYL）HETARYL）ARYLSULFONAMIDES
公开(公告)号：WO2009038847A1
公开(公告)日：2009-03-26
申请号：PCT/US2008/067351
申请日：2008-06-18
申请人： CHEMOCENTRYX, INC. , CHARVAT, Trevor, T. , HU, Cheng , MELIKIAN, Anita , NOVACK, Aaron , PENNELL, Andrew, M.K. , POWERS, Jay , PUNNA, Sreenivas , SULLIVAN, Edward, J. , THOMAS, William, D. , UNGASHE, Solomon , ZHANG, Penglie
发明人： CHARVAT, Trevor, T. , HU, Cheng , MELIKIAN, Anita , NOVACK, Aaron , PENNELL, Andrew, M.K. , POWERS, Jay , PUNNA, Sreenivas , SULLIVAN, Edward, J. , THOMAS, William, D. , UNGASHE, Solomon , ZHANG, Penglie
IPC分类号： C07D209/08 , C07D231/12 , C07D231/14 , C07D231/16 , C07D231/56 , C07D233/61 , C07D235/08 , C07D249/06 , C07D249/18 , C07D401/04 , C07D401/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D471/04
CPC分类号： C07D473/00 , A61K31/404 , A61K31/415 , A61K31/4164 , A61K31/4192 , A61K31/437 , A61K31/496 , A61K31/52 , A61K31/5377 , A61K45/06 , C07D209/08 , C07D231/12 , C07D231/14 , C07D231/16 , C07D231/56 , C07D233/61 , C07D235/06 , C07D235/08 , C07D249/06 , C07D249/18 , C07D401/04 , C07D401/14 , C07D403/06 , C07D413/04 , C07D413/14 , C07D417/04 , C07D471/04 , C07D487/04 , C12N2501/999
摘要： Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
摘要翻译：提供了作为CCR9受体的有效拮抗剂的化合物。动物实验表明，这些化合物可用于治疗炎症，CCR9的特征性疾病。化合物通常为芳基磺酰胺衍生物，并且可用于药物组合物，用于治疗CCR9介导的疾病的方法，以及用于鉴定CCR9拮抗剂的测定中的对照。

7. 发明申请

WO2009009740A1 FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREAMENT OF INFLAMMATION 审中-公开
标题翻译： FUSED HETEROARYL PYRIDYL和PHENYL BENZENESUFLONAMIDES作为CCR2调节剂用于炎症反应
公开(公告)号：WO2009009740A1
公开(公告)日：2009-01-15
申请号：PCT/US2008/069813
申请日：2008-07-11
申请人： CHEMOCENTRYX, INC. , KRASINSKI, Antoni , PUNNA, Sreenivas , UNGASHE, Solomon , WANG, Qiang , ZENG, Yibin
发明人： KRASINSKI, Antoni , PUNNA, Sreenivas , UNGASHE, Solomon , WANG, Qiang , ZENG, Yibin
IPC分类号： A61K31/519 , C07D473/00 , C07D487/04 , A61P29/00
CPC分类号： C07D487/04 , C07D213/79 , C07D213/81 , C07D213/84 , C07D471/04 , C07D471/12 , C07D473/00
摘要： Compounds are provided that act as potent antagonists of the CCR2 receptor. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2- mediated diseases and as controls in assays for the identification of CCR2 antagonists. A compound of the formula (I) or a salt thereof: where: R 1 and R 2 are each independently hydrogen, halogen, C 1-8 alkyl, -CN. or C 1-8 haloalkyl, provided that at least one of R1 1 or R 2 is other than hydrogen; each R 3 is independently hydrogen; R 4 is hydrogen; R 5 is halogen or C 1-8 alkyl; R 6 is hydrogen; X 1 is CR 7 , N or NO; X 2 and X 4 are N or NO; X 3 is CR 7 ; X 6 and X 7 are each independently selected from CR 7 , N, and NO; each R 7 is independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C 2-8 alkyl, substituted or unsubstituted C 2-8 alkeπyl, substituted or unsubstituted C 2-8 alkynyl, -CN. =O, -NO 2 , -OR 6 , -OC(O)R 8, -CO 2 R 8, -C(O)R 8 , -C(O)NR 0 R 8 , -OC(O)NR 9 R 8 , -NR 10 C(O)R 8 , -NR 10 C(O)NR 9 R 8 , -NR 9 R 8 , -NR 10 CO 2 R 8 , -SR 8 , -S(O)R 8 , -S(O) 2 R 8 , -S(O) 2 NR 9 R 8 , -NR 10 S(O) 2 R 8 , substituted or unsubstituted C 6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl and substituted or unsubstituted 3- to 10-membered heterocyclyl;
摘要翻译：提供了作为CCR2受体的有效拮抗剂的化合物。化合物通常为芳基磺酰胺衍生物，并且可用于药物组合物，用于治疗CCR2-介导的疾病的方法和用于鉴定CCR2拮抗剂的测定中的对照。式（I）的化合物或其盐：其中：R 1和R 2各自独立地为氢，卤素，C 1-8烷基，-CN。或C 1-8卤代烷基，条件是R 11或R 2中的至少一个不是氢; 每个R 3独立地是氢; R4是氢; R5是卤素或C1-8烷基; R6是氢; X1为CR7，N或NO; X2和X4为N或NO; X3是CR7; X 6和X 7各自独立地选自CR 7，N和NO; 每个R 7独立地选自氢，卤素，取代或未取代的C 2-8烷基，取代或未取代的C 2-8烷基，取代或未取代的C 2-8炔基-CN。 = O，-NO 2，-OR 6，-OC（O）R 8，-CO 2 R 8，-C（O）R 8，-C（O）NR 0 R 8，-OC（O）NR 9 R 8，-NR 10 C（O） O）NR9R8，-NR9R8，-NR10CO2R8，-SR8，-S（O）R8，-S（O）2R8，-S（O）2NR9R8，-NR10S（O）2R8，取代或未取代的C6-10芳基，或未取代的5-至10-元杂芳基和取代或未取代的3-至10-元杂环基;

8. 发明申请

WO2017176620A3 SOLUBLE C5aR ANTAGONISTS 审中-公开
公开(公告)号：WO2017176620A3
公开(公告)日：2017-10-12
申请号：PCT/US2017/025704
申请日：2017-04-03
申请人： CHEMOCENTRYX, INC.
发明人： FAN, Pingchen , KRASINSKI, Antoni , MALI, Venkat, Reddy , MIAO, Shichang , PUNNA, Sreenivas , SONG, Yang , STELLA, Valentino, J. , ZENG, Yibin , ZHANG, Penglie
IPC分类号： A61K31/451 , C07D211/60
摘要： Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R 1 , R 2 and R 3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

9. 发明申请

WO2014089495A1 DIAZOLE LACTAMS 审中-公开
公开(公告)号：WO2014089495A1
公开(公告)日：2014-06-12
申请号：PCT/US2013/073692
申请日：2013-12-06
申请人： CHEMOCENTRYX, INC.
发明人： CHEN, Xi , FAN, Pingchen , LI, Yandong , POWERS, Jay P. , MALATHONG, Viengkham , PUNNA, Sreenivas , TANAKA, Hiroko , ZHANG, Penglie
IPC分类号： A61K31/497
CPC分类号： A61K31/4178 , A61K31/4155 , A61K31/4192 , A61K31/4196 , A61K45/06 , C07D401/14 , C07D403/14 , C07D405/14 , C07D471/04 , C07D487/04 , A61K2300/00
摘要： Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are diazole lactam derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.
摘要翻译：提供了作为CCR1受体的有效拮抗剂并具有体内抗炎活性的化合物。这些化合物是二唑内酰胺衍生物，并且可用于药物组合物，用于治疗CCR1介导的疾病的方法，以及用于鉴定竞争性CCR1拮抗剂的测定中的对照。

10. 发明申请

WO2019126431A1 DIARYL SUBSTITUTED 5,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS 审中-公开
公开(公告)号：WO2019126431A1
公开(公告)日：2019-06-27
申请号：PCT/US2018/066677
申请日：2018-12-20
申请人： CHEMOCENTRYX, INC.
发明人： FAN, Pingchen , LANGE, Christopher W. , LUI, Rebecca M. , MALATHONG, Viengkham , MALI, Venkat Reddy , PUNNA, Sreenivas , SINGH, Rajinder , ZENG, Yibin , ZHANG, Penglie
IPC分类号： C07D231/56 , C07D471/04
摘要： The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式